Human endogenous retroviruses as epigenetic therapeutic targets in TP53-mutated diffuse large B-cell lymphoma

TP53 mutation (TP53(mut)) occurs in 10–20% of diffuse large B-cell lymphoma (DLBCL) cases and serves as an unfavorable biomarker of DLBCL progression. It confers resistance to immunochemotherapy, high-dose chemotherapy, autologous stem cell transplantation, and anti-CD19 chimeric antigen receptor T-...

Descripción completa

Detalles Bibliográficos
Autores principales: Fang, Ying, Zhang, Mu-Chen, He, Yang, Li, Chen, Fang, Hai, Xu, Peng-Peng, Cheng, Shu, Zhao, Yan, Feng, Yan, Liu, Qian, Wang, Li, Zhao, Wei-Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10556001/
https://www.ncbi.nlm.nih.gov/pubmed/37798292
http://dx.doi.org/10.1038/s41392-023-01626-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10556001/
https://www.ncbi.nlm.nih.gov/pubmed/37798292
http://dx.doi.org/10.1038/s41392-023-01626-x

Ejemplares similares